Triple

T24850896
Position Surface form Disambiguated ID Type / Status
Subject RNA therapeutics E621880 entity
Predicate regulatoryApprovedExample P24602 FINISHED
Object eteplirsen
Eteplirsen is an antisense oligonucleotide drug used to treat Duchenne muscular dystrophy by promoting exon 51 skipping during dystrophin mRNA processing.
 E1654314 NE FINISHED

How this triple was built (3 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: eteplirsen | Statement: [RNA therapeutics, regulatoryApprovedExample, eteplirsen]
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: eteplirsen
Triple: [RNA therapeutics, regulatoryApprovedExample, eteplirsen]
Generated description
Eteplirsen is an antisense oligonucleotide drug used to treat Duchenne muscular dystrophy by promoting exon 51 skipping during dystrophin mRNA processing.
PD Predicate disambiguation gpt-5-mini-2025-08-07 
Target predicate: regulatoryApprovedExample
Context triple: [RNA therapeutics, regulatoryApprovedExample, eteplirsen]
  • A. hasRegulatoryApproval chosen
    Indicates that an entity has received formal authorization or clearance from a relevant regulatory authority to operate, be sold, or be used in a specified context.
  • B. regulationStatus
    Indicates the regulatory condition or compliance state that applies to an entity under relevant rules or laws.
  • C. hasRegulatedBy
    Indicates that one entity is subject to control, governance, or rules imposed by another entity.
  • D. regulatoryOutcome
    Indicates the result or consequence of a regulatory process, such as approval, rejection, modification, or other formal decision made by a regulatory authority regarding an entity or action.
  • E. appliesRegulatoryStandard
    Indicates that one entity enforces or uses a specific regulatory standard in relation to another entity or context.
  • F. None of above.

Provenance (6 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e2fac297e481909d3aedc75f585e42 completed April 18, 2026, 3:30 a.m.
NER Named-entity recognition batch_69f61f12b0f08190bc4a16907941864c completed May 2, 2026, 3:58 p.m.
NED1 Entity disambiguation (via context triple) batch_6a101c533540819094411da3f6178d1d completed May 22, 2026, 9:05 a.m.
NEDg Description generation batch_6a102814f838819094ed41d653039f72 completed May 22, 2026, 9:55 a.m.
NED2 Entity disambiguation (via description) batch_6a10294485508190a91d9ec391181047 completed May 22, 2026, 10 a.m.
PD Predicate disambiguation batch_69f61b37a5648190b10d33ae205ccfee completed May 2, 2026, 3:41 p.m.
Created at: April 18, 2026, 5:20 a.m.